FIG. 1A




FIG. 1B




FIG. 1C





FIG. 1D





FUGENE® HD
LIPOFECTAMINE® 2000
LIPOFECTAMINE® 3000 + Peptide
HEK293
HeLa
Cos7
LNCaP
A549
HepG2

FIG. 2



% Transfection
% Transfection
100
90
80
70
60
50
40
30
20
10
0
0.1
0.2
0.3
0.4
Dose (µl)
LIPOFECTAMINE® 2000
LIPOFECTAMINE® 3000
+ Peptide
LIPOFECTAMINE® LTX

FIG. 3A



Intensity of Expression vs. Lipid Dose
Intensity of Expression (RLU)
500000
450000
400000
350000
300000
250000
200000
150000
100000
50000
0
0.1
0.2
0.3
0.4
Dose (µl)
LIPOFECTAMINE® 2000
LIPOFECTAMINE® 3000
+ Peptide
LIPOFECTAMINE® LTX

FIG. 3B



LIPOFECTAMINE® 2000
LIPOFECTAMINE® 3000 + Peptide
FUGENE® HD
X-TREMEGENE™ HP
GST-STAT
β-actin
HepG2

FIG. 4



LIPOFECTAMINE® 2000
LIPOFECTAMINE® 3000 + Peptide
DNA Dose(µg)
50
100
200
% GFP + Cells
0
10
20
30
40
50
0.1
0.3
0.5
Reagent Dose (µl per 96 well)
37500
Density

FIG. 5A



18%
52%

FIG. 5B



Cell Type U20S
Mean OFP Intensity
200,000
150,000
100,000
50,000
0
3µL LIPOFECTAMINE® 2000
1.5µL LIPOFECTAMINE® 3000
+ Peptide

FIG. 6A



Cell Type HepG2
Mean OFP Intensity
200,000
150,000
50,000
0
3µL LIPOFECTAMINE® 2000
1.5µL LIPOFECTAMINE® 3000
+ Peptide

FIG. 6B



1 kb Ladder
U20S
500
400
300
200
100
% Gene Modification Efficiency
20
15
10
5
0
TALENs
CRISPR
TALENs
CRISPR
LIPOFECTAMINE® 2000
LIPOFECTAMINE® 3000 + Peptide

FIG. 7A



1 kb Ladder
HepG2
650
500
400
300
200
% Gene Modification Efficiency
10
5
0
TALENs
CRISPR
TALENs
CRISPR
LIPOFECTAMINE® 2000
LIPOFECTAMINE® 3000 + Peptide

FIG. 7B



GFP+ as % of Single Cells Only
Single Cells Only Mean FL1-H
0
20
40
60
80
100000
200000
300000
400000
500000
d_0.05
d_0.1
d_0.2
d_0.3
d_0.4
d_0.5
LF3K
LF2K
Peptide 1
LF3K + Peptide 1
Reagent Dose
(µl)

FIG. 8



D
MPP
Linker
Cationic
Peptide Map
A
B
C
E

FIG. 9A



Peptide A
Peptide B
Peptide C
Peptide D
Peptide A + B
Peptide A + C
Peptide A + D
Peptide B + C
Peptide E

FIG. 9B



Cell Line
HepG2
Mean Fluorescence/cell
150000
100000
50000
0
%GFP + Cells
60
50
40
30
20
10
0
-10
A A+B A+C A+D B B+C C D E A A+B A+C A+D B B+C C D E
Peptide
LF3K
no LF3K
Treatment/Peptide Label

FIG. 9C




FIG. 10A




FIG. 10B



Cell Line
A549
Mean Fluorescence/cell
150000
100000
50000
0
%GFP + Cells
80
60
40
20
0
A A+B A+C A+D B B+C C D E
LF3K
A A+B A+C A+D B B+C C D E
no LF3K
Treatment/Peptide Label
Peptide

FIG. 10C




FIG. 11A




FIG. 11B



Cell Line
MDA-MB-231
Mean Fluorescence/cell
40000
30000
20000
10000
0
%GFP + Cells
40
30
20
10
0
A
A+B
A+C
A+D
B
B+C
C
D
E
LF3K
A
A+B
A+C
A+D
B
B+C
C
D
E
no LF3K
Peptide
Treatment/Peptide Label

FIG. 11C